Obagi Treatments

Treatment of Moderate or Marked Melasma in Darker Skin with a 4% Hydroquinone Skin Care System Plus 0.05% Tretinoin Cream

Michael Gold, MD Nashville, TN
Marta Rendon, MD, Boca Raton, FL
Barry DiBernardo, MD Montclair, NJ
Suzanne Bruce, MD Houston, TX
Chere Lucas-Anthony, MD Boca Raton, FL
JoAnne Watson, DPM Long Beach, CA
Funded by OPM, Inc.


Conflicts of Interest


  • Dr Gold – consultant, investigator, and speaker for OPM, Inc.
  • Dr Rendon – investigator for OMP, Inc.
  • Dr DiBernardo – consultant and investigator for OMP, Inc.
  • Dr Bruce – consultant and investigator for OMP, Inc.
  • Dr Lucas-Anthony – investigator for OMP, Inc.
  • Dr Watson – employee of, and holds stock and stock options in, OMP, Inc.


Purpose



  • To evaluate the efficacy and tolerability of treating melasma in darker skin using a 4% hydroquinone skin care system plus 0.05% tretinoin cream
[This regimen treats melasma and provides a complete skin care routine]


Rationale for Study



  • A previous study1 has evaluated the efficacy and safety of treating mild or moderate epidermal melasma in darker skin using a 4% hydroquinone skin care system plus 0.025% tretinoin cream
  • Study presented here has similar protocol except:
  • Evaluates higher concentration of tretinoin
(0.05% rather than 0.025%) -      Evaluates moderate or marked melasma
(rather than mild or moderate melasma)

1 Grimes & Watson, Eposter 4581, AAD March 2012


Inclusion Criteria

  • 25- to 65-year old females with:
  • - Moderate or marked epidermal melasma (covering 26% to 50% of face), confirmed by Wood’s lamp examination
  • - Mild to marked intensity of melasma pigmentation
  • - Cutaneous melanosis stable over preceding 3 months
  • - Fitzpatrick skin type III-VI

Improvements in Melasma

Obagi treatment
1 2 3 4 5 6 7 8 9

Services